Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed Combined With Bevacizumab Intrathecal Injection in NSCLC Leptomeningeal Metastases
NCT06663306Phase 1Recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of bevacizumab in non-small cell lung cancer (NSCLC) and leptomeningeal metastasis (LM) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Incidence of Adverse Events at 2 months. Started Dec 2024; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT06663306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06663306.